RVMDW Projected Dividend Yield

Revolution Medicines Inc ( NASDAQ : RVMDW )

Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. Co.'s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which Co. refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target main nodes in the RAS pathway or associated pathways, which Co. refers to as RAS Companion Inhibitors. Co.'s RAS Companion Inhibitors (example, SHP2, mTORC1 and SOS1 inhibitors) are designed primarily for combination treatment strategies involving one or more therapeutic agents, which may include its RAS(ON) Inhibitors.

20 YEAR PERFORMANCE RESULTS